Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

PD-1/PD-L1 Inhibitors Market Outlook (2023 to 2033)

The PD-1/PD-L1 inhibitors market size is projected to be valued at US$ 49.5 billion in 2023 and is expected to reach a valuation of US$ 123.3 billion by 2033. The market is also expected to record a significant CAGR of 9.6% during the forecast period.

Significant Aspects Influencing the Market

  • Cancer immunotherapy has advanced significantly in recent years, with PD-1/PD-L1 immunotherapy emerging as one of the most prominent therapies.
  • Many clinical trials have demonstrated their significance, and many more are still being conducted to identify other cancers that can be treated with this therapy.
  • Innovative insights into how the human immune system responds to and is formed by diverse tumor types are likely to be produced through dynamic immunologic investigations, which are also anticipated to direct the development of combination medicines. These investigations are likely to contribute to the understanding of genetics and epigenetics in the microenvironment of human cancer.
  • In comparison to their counterparts, immune checkpoint inhibitor drugs have a high target affinity and specificity. Rising approval ratings for these drugs and lower costs are likely to drive product demand.
  • Immune checkpoint inhibitor drugs were discovered to be a better alternative to most approved therapies, which have severe side effects during cancer treatments. As a result, the market for immune checkpoint inhibitors has grown tremendously among healthcare professionals in recent years.
  • Immune checkpoint inhibitors are highly specific, making them far more effective than conventional treatments.

Limiting Aspects of the Market

Regardless of the various factors influencing the growth of this market, several key issues must be addressed to facilitate future growth. The relatively high total costs of developing and using PD-1/PD-L1 inhibitors, as well as reimbursement policies, are limiting the market's growth.

Attributes Details
PD-1/PD-L1 Inhibitors Market CAGR 9.6 %
PD-1/PD-L1 Inhibitors Market Valuation (2023) US$ 49.5 billion
PD-1/PD-L1 Inhibitors Market Valuation (2033) US$ 123.3 billion

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

How The Market Progressed till June 2022?

Market Statistics Details
H1,2021 (A) 13.19%
H1,2022 Projected (P) 10.71%
H1,2022 Outlook (O) 9.61%
BPS Change: H1,2022 (O) - H1,2022 (P) (-) 110 ↓
BPS Change: H1,2022 (O) - H1,2021 (A) (-) 349 ↓

According to Future Market Insights' analysis, the global PD-1/PD-L1 inhibitors market dropped by 349 Basis Point Share (BPS) in H1-2022 as compared to H1- 2021. Whereas in comparison to H1-2022 projected value, the market during the H1-2022 outlook period showed a dip of 110 BPS.

The drop in the BPS values is associated with the reported resistance to PD-1/PD-L1 therapy among patients, with only a few estimated to present a positive outlook of treatment. Due to the need for developing predictive biomarkers, the industry noticed a decline in the linked BPS values with low frequencies of positive clinical outcomes. The FDA has approved 10 immune checkpoint inhibitors for the PD-1/PD-L1 pathway till 2018. The growth in FDA approvals for clinical therapy with PD1/PDL1 inhibitors is expected to provide the market landscape with a positive growth outlook for the forecast years. For instance, six anti-PD-1/PD-L1 mAbs (monoclonal antibodies) have received approval as of December 2020, with indications covering 19 different cancer types and two tissue-agnostic diseases.

Key developments in the market include the development of monoclonal antibodies for targeted therapeutic approaches. The market is subject to changes as per drug trial assessment and regulatory impositions, in accordance with the macro and industry standards.

2018 to 2022 PD-1/PD-L1 Inhibitors Market Outlook in Comparison to 2023 to 2033 Growth Forecast

Leading industry players are concentrating on the development and commercialization of novel PD-1/PD-L1 inhibitors to treat a variety of cancers. The expansion in the market availability of PD-1/PD-L1 immunotherapeutic is expected to drive the growth of the PD-1/PD-L1 inhibitors market.

The global PD-1/PD-L1 Inhibitors market is expected to expand due to an increase in cancer incidence. PD-1/PD-L1 inhibitors, for example, are important Immune Checkpoint Inhibitors (ICIs) used as first-line treatments for a variety of cancers. Cancer was one of the leading causes of death worldwide in 2020, accounting for around ten million deaths, or nearly one in every six deaths, according to the World Health Organization (WHO). Breast, lung, colon, rectum, and prostate are the most common cancers. As a result, there is a global increase in demand for PD-1 and PD-L1 inhibitors.

The Union for International Cancer Control (UICC) estimates that older individuals (those 65 and older) have an 11-fold increased risk of cancer compared to younger individuals. According to the United Nations, there are over 703 million people aged 65 and up, with that number expected to rise to 1.5 billion by 2050. According to the most recent United Nations DESA population division estimates and projections, one in every six people in the world is likely to be over the age of 65 by 2050, up from one in every eleven in 2019.

Considering this, FMI expects the global PD-1/PD-L1 inhibitors market to record a CAGR of 9.6% through 2033.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What Factors are Restraining Demand for PD-1/PD-L1 Inhibitors?

The high cost of cancer immunotherapy and stringent regulatory scenario are the primary factors hampering the PD-1/PD-L1 inhibitors market over the forecast period.

Cancer treatment costs generate substantial economic issues for healthcare providers and patients because of the impact they have on patient safety, quality of care, and overall healthcare. The high cost of cancer therapy is anticipated to slow down the rate of treatment uptake, particularly in emerging nations. The regulatory requirements are expected to be strengthened as biologics move through clinical studies and into commercial production. Biologics must be rigorously verified and monitored against critical quality attributes (CQAs) throughout the manufacturing process, not just at the end like chemistry-based medications, due to the nature of biologics, which are created by live cells. This makes it more difficult for biologics to obtain regulatory approval, which restricts market expansion.

Comparative View of PD-1/PD-L1 Inhibitors Market

PD-1/PD-L1 Inhibitors Market:

Attributes PD-1/PD-L1 Inhibitors Market
CAGR (2023 to 2033) 9.6%
Market Value (2033) US$ 123.3 billion
Growth Factor The rising cancer prevalence, as well as technological innovations and advancements in cancer screening procedures, are driving market growth for PD-1 and PD-L1 inhibitors.
Opportunity Increased public awareness and increased government cancer-fighting initiatives are expected to drive the market forward.

Low Dosage Hydrate Inhibitors Market:

Attributes Low Dosage Hydrate Inhibitors Market
CAG (2023 to 2033) 8.1%
Market Valu (2033) US$ 127.45 million.
Growth Factor Low-dosage hydrate inhibitors' ability to reduce transportation and handling costs through decreased delivery frequency and chemical consumption is expected to drive market sales.
Opportunity Increased crude oil exploration and production are expected to drive market growth, as low-dosage hydrate inhibitors are widely used in extraction processes to reduce hydrate formation in the systems.

Kinase Inhibitors For Cancer Treatment Market:

Attributes Kinase Inhibitors For Cancer Treatment Market
CAGR (2023 to 2033) 10.5%
Market Value (2033) US$ 122,133.64 million
Growth Factor Pharmaceutical companies are currently investing heavily in research and development activities to develop improved kinase inhibitors. This is currently driving the market growth.
Opportunity Massive technological advancements are taking place in the healthcare sector, particularly in the field of cancer treatment.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-wise Analysis

In 2023, the United States is expected to account for around 98.9% of the North American PD-1/PD-L1 inhibitors market

The dominance of the United States can be attributed primarily to the rising prevalence of several chronic diseases such as lung cancers, urothelial carcinomas, skin cancer, and diabetes in the United States, which necessitated efficient treatment.

According to the American Cancer Society's 2020 report, lung cancer is the second leading cause of death for both men and women, accounting for 135,720 deaths. According to the statistics, nearly 84% of all lung cancers in the United States are NSCLC (non-small cell lung cancer) and 13% are SCLC (small cell lung cancer), which is expected to continue in the coming years, resulting in an increasing demand for PD-1/PD-L1 Inhibitors in the country.

Attributes Details
United States Market Size (US$ million/billion) by End of Forecast Period (2033) US$ 23.4 billion
United States Market Absolute Dollar Growth (US$ million/billion) US$ 2.9 billion
CAGR % 2018 to 2022 31.0%
CAGR % 2023 to End of Forecast (2033) 8.4%

In 2023, Germany is expected to account for 26.7% of the PD-1/PD-L1 inhibitors market in Europe

Germany is expected to expand more rapidly than the rest of Europe, owing to several clinical trials being conducted in the industry.

Organizations such as the European Medicines Agency have increased their focus on PD-1/PD-L1 inhibitors for combination therapy and monotherapy use, intending to treat diseases in adults as well as in pediatric trials. The growing awareness of the low toxicity levels and compliance between PD-1/PD-L1 inhibitors and regional healthcare safety regulations can be attributed to the market's growth in Germany.

Attributes Details
Germany Market Size (US$ million/billion) by End of Forecast Period (2033) US$ 3.8 billion
Germany Market Absolute Dollar Growth (US$ million/billion) US$ 508.6 million
CAGR % 2018 to 2022 43.6%
CAGR % 2023 to End of Forecast (2033) 10.4%

In the global market, the PD-1/PD-L1 inhibitors market in China is expected to be worth US$ 1.8 billion by 2033

Given its significant population base and significant private and public sector investment in healthcare infrastructure development, China is expected to expand at a relatively rapid rate during the forecast period. Also, the surge in cancer cases, combined with the growing interest in immune checkpoint inhibitors, is expected to drive market growth over the forecast period.

Besides, an increase in product launches and product innovations in oncology immunotherapy is expected to drive growth in China.

Attributes Details
China Market Size (US$ million/billion) by End of Forecast Period (2033) US$ 1.8 billion
China Market Absolute Dollar Growth (US$ million/billion) US$ 305.6 million
CAGR % 2018 to 2022 44.8%
CAGR % 2023 to End of Forecast (2033) 14.0%

In India, demand for PD-1/PD-L1 inhibitors is expected to record a CAGR of 15.4% over the forecast period.

The rising cancer incidence, increased government involvement in cancer diagnosis, the introduction of new immunotherapies with fewer side effects, and the increasing adoption of inorganic growth strategies such as collaborations, acquisitions, and mergers by key players in the market are the primary factors expected to drive the growth of the PD-1/PD-L1 inhibitors market in India during the forecast period.

Category-wise Insights

Pembrolizumab is expected to have a Sizeable Market Share of 49.5% in 2023, Growing at a rate of nearly 8.7% over the Forecast Period

Pembrolizumab, out of all the products in the PD-1/PD-L1 inhibitors market, is expected to expand significantly due to increased adoption of the product over the other products.

Pembrolizumab's increased use is due to its proven efficacy in treating various FDA-approved indications such as head and neck squamous cell cancer (HNSCC), non-small cell lung cancer (NSCLC), melanoma, and others since its approval in 2014. This is boosting the segment's growth over the forecast period. Significant investments in the development of this product by key players are driving segment sales over the forecast period.

Hospital Pharmacies are expected to have a significant share of 48.3% in 2022, Expanding at a Rapid Rate of 9.9% CAGR during the Forecast Period

The growth of the hospital pharmacy segment is due to massive orders, robust supply chains, and hospital facilities' efforts to maintain large-scale inventories for cancer therapy applications. Also, the presence of advanced equipment and the availability of well-developed infrastructure contribute to the segment's growth. Besides, as more patients are admitted to hospitals for cancer treatment, the use of PD-1/PD-L1 inhibitors in hospitals is increasing, thus boosting sales in hospital pharmacies.

The Non-small Cell Lung Cancer (NSCLC) Segment is Likely to Lead the Market, accounting for 37.0% of the total Market Revenue Share in 2023

NSCLC (non-small cell lung cancer) accounts for around 80% to 85% of all cases of lung cancer worldwide, and this significant share has encouraged several key players to focus on continuous innovation of advanced therapeutics and improving the efficacy of existing therapeutics. Growing NSCLC (non-small cell lung cancer) diagnoses and rising awareness in developing and developed markets are driving the growth of the non-small cell lung cancer segment.

Competitive Background

The global adoption of PD-1/PD-L1 inhibitors has prompted companies to invest in the development of products in the PD-1/PD-L1 immunotherapy segment for cancer treatment. Merck & Co., Inc. has been a pioneer in this field and a significant competitor in this market due to its diverse product portfolio and intense market penetration.

Recent Developments

  • Bristol Myers Squibb received a favorable opinion from the committee for medicinal products for human use (CHMP) in July 2022, recommending approval of the LAG-3-blocking antibody combination Opdualag (nivolumab and relatlimab) for the treatment of patients with unresectable or metastatic melanoma.
  • Merck received the United States FDA approval for KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1, as determined by an FDA-approved test, in October 2021.

Leading Companies Operating in the PD-1/PD-L1 Inhibitors Market are

  • Akeso Inc.
  • Alphamab Oncology
  • Amgen Inc.
  • AstraZeneca Plc
  • BeiGene Ltd.
  • Bristol Myers Squibb Co.
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Innovent Biologics Inc.
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Merck and Co. Inc.

Scope of Report

Attribute Details
Forecast Period 2023 to 2033
Historical Data Available for 2018 to 2022
Market Analysis US$ million for Value
Key Countries Covered United States, Canada, Germany, United Kingdom, France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Türkiye, Northern Africa, and South Africa
Key Segments Covered
  • Product
  • Indication
  • Distribution Channel
  • Region
Key Companies Profiled
  • Akeso Inc.
  • Alphamab Oncology
  • Amgen Inc.
  • AstraZeneca Plc
  • BeiGene Ltd.
  • Bristol Myers Squibb Co.
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Innovent Biologics Inc.
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • o Merck and Co. Inc.
Report Coverage Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
Customization & Pricing Available upon Request

PD-1/PD-L1 Inhibitors Market by Category

By Product:

  • Nivolumab
  • Pembrolizumab
  • Atezolizumab
  • Avelumab
  • Durvalumab

By Indication:

  • Melanoma
  • Non-Small Cell Lung Cancer (NSCLC)
  • Renal Cell Carcinoma (RCC)
  • Head and Neck Squamous Cell Cancer (HNSCC)
  • Bladder Cancer
  • Merkel Cell Carcinoma (MCC)
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia & Pacific
  • East Asia
  • The Middle East & Africa (MEA)

Frequently Asked Questions

How Big is the PD-1/PD-L1 Inhibitors Market?

The market is valued at US$ 49.5 billion in 2023.

What is the Projected Market CAGR from 2023 to 2033?

The market is anticipated to record a CAGR of 9.6%.

What is the Market Share of Germany in 2023?

Germany is expected to account for 26.7% of the market in 2023.

How Big will the PD-1/PD-L1 Inhibitors Market in 2033?

The market is estimated to reach US$ 123.3 billion.

What is United States Market CAGR over the Forecast Period?

The United States is projected to expand at a CAGR of 8.4% over the forecast period.

Table of Content

1. Executive Summary | PD-1/PD-L1 Inhibitors Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Nivolumab

        5.3.2. Pembrolizumab

        5.3.3. Atezolizumab

        5.3.4. Avelumab

        5.3.5. Durvalumab

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033

        6.3.1. Melanoma

        6.3.2. Non-Small Cell Lung Cancer

        6.3.3. Renal Cell Carcinoma

        6.3.4. Head and Neck Squamous Cell Cancer

        6.3.5. Bladder Cancer

        6.3.6. Merkel Cell Carcinoma

    6.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Drug Class

        9.2.3. By Indication

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Indication

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Class

        10.2.3. By Indication

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Indication

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Drug Class

        11.2.3. By Indication

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Indication

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Drug Class

        12.2.3. By Indication

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Indication

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Drug Class

        13.2.3. By Indication

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Indication

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Drug Class

        14.2.3. By Indication

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Indication

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Drug Class

        15.2.3. By Indication

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Class

        15.3.3. By Indication

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Drug Class

            16.1.2.2. By Indication

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Drug Class

            16.2.2.2. By Indication

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Drug Class

            16.3.2.2. By Indication

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Drug Class

            16.4.2.2. By Indication

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Drug Class

            16.5.2.2. By Indication

            16.5.2.3. By Distribution Channel

    16.6. United kingdom

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Drug Class

            16.6.2.2. By Indication

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Drug Class

            16.7.2.2. By Indication

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Drug Class

            16.8.2.2. By Indication

            16.8.2.3. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Drug Class

            16.9.2.2. By Indication

            16.9.2.3. By Distribution Channel

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Drug Class

            16.10.2.2. By Indication

            16.10.2.3. By Distribution Channel

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Drug Class

            16.11.2.2. By Indication

            16.11.2.3. By Distribution Channel

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Drug Class

            16.12.2.2. By Indication

            16.12.2.3. By Distribution Channel

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Drug Class

            16.13.2.2. By Indication

            16.13.2.3. By Distribution Channel

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Drug Class

            16.14.2.2. By Indication

            16.14.2.3. By Distribution Channel

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Drug Class

            16.15.2.2. By Indication

            16.15.2.3. By Distribution Channel

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Drug Class

            16.16.2.2. By Indication

            16.16.2.3. By Distribution Channel

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Drug Class

            16.17.2.2. By Indication

            16.17.2.3. By Distribution Channel

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Drug Class

            16.18.2.2. By Indication

            16.18.2.3. By Distribution Channel

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Drug Class

            16.19.2.2. By Indication

            16.19.2.3. By Distribution Channel

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Drug Class

            16.20.2.2. By Indication

            16.20.2.3. By Distribution Channel

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Drug Class

            16.21.2.2. By Indication

            16.21.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Drug Class

        17.3.3. By Indication

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Merck Co. & Inc.

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Bristol-Myers Squibb

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. F. Hoffmann-La Roche AG

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. AstraZeneca Plc.

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Pfizer Inc.

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Merck KGaA

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Sanofi AG

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Amgen Inc.

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Regeneron Pharmaceuticals Inc.

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Novartis AG

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Chiari Malformation Treatment Market

Published : March 2023

Healthcare

Carcinoid Tumor Syndrome Management Market

Published : March 2023

Explore Healthcare Insights

View Reports

PD-1/PD-L1 Inhibitors Market